These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 18650512)

  • 1. Raltegravir with optimized background therapy for resistant HIV-1 infection.
    Steigbigel RT; Cooper DA; Kumar PN; Eron JE; Schechter M; Markowitz M; Loutfy MR; Lennox JL; Gatell JM; Rockstroh JK; Katlama C; Yeni P; Lazzarin A; Clotet B; Zhao J; Chen J; Ryan DM; Rhodes RR; Killar JA; Gilde LR; Strohmaier KM; Meibohm AR; Miller MD; Hazuda DJ; Nessly ML; DiNubile MJ; Isaacs RD; Nguyen BY; Teppler H;
    N Engl J Med; 2008 Jul; 359(4):339-54. PubMed ID: 18650512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.
    Cooper DA; Steigbigel RT; Gatell JM; Rockstroh JK; Katlama C; Yeni P; Lazzarin A; Clotet B; Kumar PN; Eron JE; Schechter M; Markowitz M; Loutfy MR; Lennox JL; Zhao J; Chen J; Ryan DM; Rhodes RR; Killar JA; Gilde LR; Strohmaier KM; Meibohm AR; Miller MD; Hazuda DJ; Nessly ML; DiNubile MJ; Isaacs RD; Teppler H; Nguyen BY;
    N Engl J Med; 2008 Jul; 359(4):355-65. PubMed ID: 18650513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study.
    Martínez E; Larrousse M; Llibre JM; Gutiérrez F; Saumoy M; Antela A; Knobel H; Murillas J; Berenguer J; Pich J; Pérez I; Gatell JM;
    AIDS; 2010 Jul; 24(11):1697-707. PubMed ID: 20467288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial.
    Grinsztejn B; Nguyen BY; Katlama C; Gatell JM; Lazzarin A; Vittecoq D; Gonzalez CJ; Chen J; Harvey CM; Isaacs RD;
    Lancet; 2007 Apr; 369(9569):1261-1269. PubMed ID: 17434401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Raltegravir: the first HIV integrase inhibitor.
    Cocohoba J; Dong BJ
    Clin Ther; 2008 Oct; 30(10):1747-65. PubMed ID: 19014832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-HIV agents. Integrase inhibitor raltegravir makes its mark.
    TreatmentUpdate; 2007 Feb; 19(2):8-9. PubMed ID: 17447316
    [No Abstract]   [Full Text] [Related]  

  • 7. A trial of three antiretroviral regimens in HIV-1-infected children.
    Luzuriaga K; McManus M; Mofenson L; Britto P; Graham B; Sullivan JL;
    N Engl J Med; 2004 Jun; 350(24):2471-80. PubMed ID: 15190139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.
    Prescrire Int; 2008 Aug; 17(96):135-7. PubMed ID: 19480091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
    Walmsley S; Bernstein B; King M; Arribas J; Beall G; Ruane P; Johnson M; Johnson D; Lalonde R; Japour A; Brun S; Sun E;
    N Engl J Med; 2002 Jun; 346(26):2039-46. PubMed ID: 12087139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption.
    Canducci F; Barda B; Ceresola E; Spagnuolo V; Sampaolo M; Boeri E; Nozza S; Cossarin F; Galli A; Gianotti N; Castagna A; Lazzarin A; Clementi M
    Clin Microbiol Infect; 2011 Jun; 17(6):928-34. PubMed ID: 20854427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team.
    Pialoux G; Raffi F; Brun-Vezinet F; Meiffrédy V; Flandre P; Gastaut JA; Dellamonica P; Yeni P; Delfraissy JF; Aboulker JP
    N Engl J Med; 1998 Oct; 339(18):1269-76. PubMed ID: 9791142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-HIV agents. Raltegravir (Isentress)--results after one year.
    TreatmentUpdate; 2007; 19(6):8-9. PubMed ID: 18041152
    [No Abstract]   [Full Text] [Related]  

  • 13. Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies.
    Canducci F; Sampaolo M; Marinozzi MC; Boeri E; Spagnuolo V; Galli A; Castagna A; Lazzarin A; Clementi M; Gianotti N
    AIDS; 2009 Feb; 23(4):455-60. PubMed ID: 19165083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial.
    Gallien S; Braun J; Delaugerre C; Charreau I; Reynes J; Jeanblanc F; Verdon R; de Truchis P; May T; Madelaine-Chambrin I; Aboulker JP; Molina JM;
    J Antimicrob Chemother; 2011 Sep; 66(9):2099-106. PubMed ID: 21712241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.
    Deeks SG; Wrin T; Liegler T; Hoh R; Hayden M; Barbour JD; Hellmann NS; Petropoulos CJ; McCune JM; Hellerstein MK; Grant RM
    N Engl J Med; 2001 Feb; 344(7):472-80. PubMed ID: 11172188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
    AIDS; 2000 Mar; 14(4):367-74. PubMed ID: 10770538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase.
    Murray JM; Emery S; Kelleher AD; Law M; Chen J; Hazuda DJ; Nguyen BY; Teppler H; Cooper DA
    AIDS; 2007 Nov; 21(17):2315-21. PubMed ID: 18090280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and effectiveness of raltegravir in patients with haemophilia and anti-HIV multidrug resistance.
    Mangiafico L; Perja M; Fusco F; Riva S; Mago D; Gringeri A
    Haemophilia; 2012 Jan; 18(1):108-11. PubMed ID: 21762404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Didanosine in HIV-1-infected patients experiencing failure of antiretroviral therapy: a randomized placebo-controlled trial.
    Molina JM; Marcelin AG; Pavie J; Heripret L; De Boever CM; Troccaz M; Leleu G; Calvez V;
    J Infect Dis; 2005 Mar; 191(6):840-7. PubMed ID: 15717257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy.
    Gulick RM; Mellors JW; Havlir D; Eron JJ; Gonzalez C; McMahon D; Richman DD; Valentine FT; Jonas L; Meibohm A; Emini EA; Chodakewitz JA
    N Engl J Med; 1997 Sep; 337(11):734-9. PubMed ID: 9287228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.